Skip to content

Recurrent Urinary tract infection (rUTI)

Clinical Study Of Recurrent Urinary tract infection( Tadiya Majari e Bol Mutwatir) and its management with unani medicines.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/09/045671
Enrollment
40
Registered
2022-09-19
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N390- Urinary tract infection, site notspecified

Interventions

Intervention1: Clinical Study of Recurrent Urinary tract infection(Tadiya Majari e Bol Mutwatir) and its management with unani medicines: Each patient is treated with unani formulations for 6 weeks wh

Sponsors

PG Dept of Moalejat General Medicine
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Recurrent uti with positive urine culture, 2.Patients with symptoms as follows a.Burning micturition b.Urgency, c.frequency of micturition d.Haematuria(Benign) e.Lower abdominal pain/supra pubic pain f.Fever with chills and rigor g.Nausea and vomitings 3.Patients with renal calculi.

Exclusion criteria

Exclusion criteria: 1.Complicated UTI 2.Patients with pregnancy 3.Patients with BPH 4.Chronic infections like TB; Gonorrhea; Syphills 5.Diabetes Mellitus 6.Patients with congenital abnormalities like polycystic kidney; renal agenesis; renal hypoplasia ; uretrovesical junction obstruction.

Design outcomes

Primary

MeasureTime frame
Depends on before and after treatment. Treatment will be given for the duration of 6 weeksTimepoint: Cure of the disease,relief in symptoms

Secondary

MeasureTime frame
Depends on before and after treatmentTimepoint: 1.Changes in urine culture and sensitivity i.e negative culture 2.Cure of the disease, relief in symptoms

Countries

India

Contacts

Public ContactDr Qudsiya Aaftab

Government Nizamia Tibbi College and General Hospital Charminar Hyderabad

dr.faroqui@gmail.com8801008577

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026